Celgene

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapies that leverage the biology of DNA repair for cancer treatment and synthetic lethality in autoimmune diseases. The company utilizes its expertise in DNA damage response biology to create a pipeline of small molecule therapeutics aimed at selectively targeting vulnerabilities in cancer cells and inducing their self-destruction through DNA damage overload. Cyteir's lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, which is crucial for repairing double-strand DNA breaks. The company is dedicated to addressing a variety of hematological malignancies, solid tumors, and chronic autoimmune disorders through its integrated drug development platform. Founded in 2012, Cyteir is committed to advancing next-generation therapies that can improve patient outcomes in challenging disease states.

Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative immunotherapy aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology can be applied across a wide range of clinical indications, targeting both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens for precise therapy, Anokion aims to provide effective treatment options that minimize side effects, thereby improving patient outcomes in the management of autoimmune and allergic diseases.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Aitia specializes in applying Causal AI and Digital Twins to advance drug discovery and development. The company utilizes multi-omic patient data and high-performance computing to uncover the underlying biological mechanisms of diseases, creating Digital Twins for conditions such as oncology, neurodegenerative disorders, and immunology. Their Gemini Digital Twins are actively employed to explore new therapies and expedite research and development in areas like multiple myeloma, prostate cancer, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease, with additional projects in the pipeline. Aitia collaborates with seven of the top ten pharmaceutical companies, academic research institutions, medical societies, multi-omic data firms, and patient advocacy organizations, positioning itself as a leader in the innovative intersection of technology and healthcare.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

Arrakis Therapeutics, Inc. is a biopharmaceutical company focused on developing a proprietary platform for drug discovery that targets ribonucleic acid (RNA). The company aims to identify new RNA targets and create small-molecule drug candidates, primarily addressing cancer and other genetically validated diseases. Its innovative platform combines advanced RNA bioinformatics, structural tools, chemical biology, and medicinal chemistry, facilitating the development of RNA-targeted small molecules (rSMs). Additionally, Arrakis offers SHAPEware, a software tool designed to predict RNA secondary structures and potential ligand-binding sites. Founded in 2015, Arrakis Therapeutics is headquartered in Waltham, Massachusetts, and its work enables improved treatment options for various conditions, including neurological disorders and rare genetic diseases.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York. It focuses on developing innovative therapeutics aimed at preventing cancer relapse and metastasis, which are significant contributors to cancer-related mortality. The company’s therapeutic pipeline addresses mechanisms of treatment resistance and utilizes advanced technologies, including artificial intelligence and machine learning, to analyze multi-omic and phenotypic profiles of tumors. This approach aims to generate insights that link tumor characteristics to clinical outcomes, ultimately striving to improve patient survival and quality of life by enabling longer, cancer-free lives.

Biond Biologics Ltd is a clinical-stage biopharmaceutical company based in Misgav, Israel, specializing in drug discovery and development for cancer immunotherapy and autoimmune diseases. Founded in 2016, the company focuses on creating innovative therapies that address unmet medical needs. Biond is dedicated to uncovering immunoregulatory pathways and conducting internal research on immune checkpoints and immune-evasion mechanisms. Its novel platform aims to enable antibody-targeting of intracellular immune factors, facilitating the development of immuno-oncology drugs and treatments for autoimmune disorders. Through its commitment to high-quality science and innovative approaches, Biond Biologics seeks to provide breakthrough therapies that can effectively combat critical health conditions.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.

Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016, that specializes in the development of innovative therapies for cancer treatment. The company's portfolio includes ATG-010 (selinexor), targeting hematologic malignancies such as multiple myeloma, and ATG-008 (onatasertib), an mTOR kinase inhibitor aimed at treating advanced solid tumors and hematological malignancies. Antengene's pipeline features several investigational products, including ATG-016 (eltanexor), ATG-527 (verdinexor), and ATG-019, along with pre-clinical candidates like ATG-101, a bi-specific antibody, and ATG-012, a KRAS G12C inhibitor. The company is committed to addressing unmet medical needs in Asia through its focus on the discovery, development, and commercialization of first-in-class therapeutics for various types of cancer.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, founded in 2008. The company has developed an innovative platform known as the CIVO arrayed microinjection system, which allows for the simultaneous evaluation of multiple drugs or drug combinations directly within a patient's tumor. This technology assesses efficacy, resistance, and drug synergies in the tumor's native microenvironment, overcoming the limitations of traditional systemic drug administration. By employing its clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, thereby streamlining drug development. Additionally, the technology facilitates the identification of effective drug combinations and targets using RNA interference, providing a more accurate measurement of treatment efficacy tailored to individual patient responses.

Nohla Therapeutics, Inc. is focused on developing and manufacturing ex vivo expanded universal donor cellular therapies aimed at treating cancer and other life-threatening illnesses. The company utilizes a unique umbilical cord blood expansion platform to create and expand key cancer-fighting cells, enabling treatment without the need for HLA matching. Nohla's primary offerings include a Natural Killer (NK) cell program and a hematopoietic stem cell (HSC) expansion platform, which supports the clinical development of its flagship product, Dilanubicel. This off-the-shelf, ex vivo expanded hematopoietic stem and progenitor cell product is designed for immediate use to aid in hematopoietic recovery and address chemotherapy-induced neutropenia, among other indications. Founded in 2015 and based in Seattle, Washington, Nohla Therapeutics aims to streamline treatment processes while reducing patient risk and costs compared to traditional cell therapies.

Skyhawk Therapeutics is focused on the discovery and development of small molecule therapeutics aimed at correcting RNA expression. The company utilizes proprietary technology to design small molecules that specifically target binding pocket regions on RNA, ensuring both sequence and structural specificity during critical phases of RNA splicing. This innovative approach enables the development of therapies for various conditions, including cancer, neurological disorders, and rare diseases, particularly those associated with RNA mis-splicing known as exon skipping. Founded in 2015 and headquartered in Waltham, Massachusetts, Skyhawk Therapeutics was previously known as Rare Genetix before rebranding in 2018.

Nohla Therapeutics, Inc. is focused on developing and manufacturing ex vivo expanded universal donor cellular therapies aimed at treating cancer and other life-threatening illnesses. The company utilizes a unique umbilical cord blood expansion platform to create and expand key cancer-fighting cells, enabling treatment without the need for HLA matching. Nohla's primary offerings include a Natural Killer (NK) cell program and a hematopoietic stem cell (HSC) expansion platform, which supports the clinical development of its flagship product, Dilanubicel. This off-the-shelf, ex vivo expanded hematopoietic stem and progenitor cell product is designed for immediate use to aid in hematopoietic recovery and address chemotherapy-induced neutropenia, among other indications. Founded in 2015 and based in Seattle, Washington, Nohla Therapeutics aims to streamline treatment processes while reducing patient risk and costs compared to traditional cell therapies.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapies that leverage the biology of DNA repair for cancer treatment and synthetic lethality in autoimmune diseases. The company utilizes its expertise in DNA damage response biology to create a pipeline of small molecule therapeutics aimed at selectively targeting vulnerabilities in cancer cells and inducing their self-destruction through DNA damage overload. Cyteir's lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, which is crucial for repairing double-strand DNA breaks. The company is dedicated to addressing a variety of hematological malignancies, solid tumors, and chronic autoimmune disorders through its integrated drug development platform. Founded in 2012, Cyteir is committed to advancing next-generation therapies that can improve patient outcomes in challenging disease states.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

Celularity is a clinical-stage biotechnology company focused on advancing cellular medicine through the development of off-the-shelf placental-derived allogeneic cell therapies. Its product pipeline includes unmodified and genetically modified natural killer (NK) cells, CAR-engineered T cells, and mesenchymal-like adherent stromal cells. The company targets various health conditions, including cancer, immunologic disorders, infectious diseases, and degenerative illnesses. Celularity leverages the unique biology of the placenta, aiming to create effective and accessible therapies to address significant unmet medical needs. In addition to its cell therapy initiatives, Celularity operates a bio-banking segment, which contributes substantially to its revenue.

Juno Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cell-based immunotherapies for cancer treatment. Utilizing chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies, Juno engineers T cells to target and eliminate cancer cells. The company's product pipeline includes several promising candidates, such as JCAR017, in Phase I/II trials for relapsed or refractory non-Hodgkin lymphoma and acute lymphoblastic leukemia, as well as JCAR018 for pediatric patients with CD22-positive cancers. Other candidates target various malignancies, including neuroblastoma, lung cancer, ovarian cancer, and glioblastoma. Juno collaborates with leading cancer research institutions to advance its therapies and was founded in 2013, headquartered in Seattle, Washington. In 2018, Juno became a subsidiary of Bristol-Myers Squibb Company.

Impact Biomedicines, Inc. is a biotechnology company focused on the research, development, and commercialization of innovative treatments for patients with myeloproliferative neoplasms and various cancers. Founded in 2016 and based in San Diego, California, the company is primarily developing fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor. This drug is aimed at treating myelofibrosis and polycythemia vera, with potential applications for acute myeloid leukemia and colorectal cancer. Impact Biomedicines operates as a subsidiary of Bristol-Myers Squibb Company.

RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It focuses on discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. RAPT's proprietary discovery engine has led to the advancement of two drug candidates: FLX475, which selectively inhibits the migration of immunosuppressive regulatory T cells into tumors, and RPT193, which targets type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short time frame since the company's inception. Additionally, RAPT is exploring further therapeutic targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are currently in the discovery phase.

Evelo Biosciences is a biotechnology company focused on discovering and developing oral biologics known as monoclonal microbials for the treatment of inflammatory diseases and cancer. These innovative medicines are designed to modulate systemic immunology through direct interactions with human cells in the gut, offering potential applications across a wide range of conditions, including autoimmune and neuroinflammatory diseases, as well as various cancers. Evelo's lead product, EDP1815, is currently undergoing clinical trials for psoriasis and atopic dermatitis, while other candidates are in preclinical stages for conditions such as psoriatic arthritis, asthma, and colorectal cancer. Founded in 2014 and based in Cambridge, Massachusetts, Evelo aims to enhance the efficiency and effectiveness of drug discovery by leveraging naturally occurring microbial entities with defined therapeutic effects.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, specializing in the discovery and development of novel therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which combines genome-wide and CRISPR-enabled technology, the company systematically identifies targeted cancer therapies addressing genomic instability, particularly in DNA damage repair. Its lead candidate, RP-3500, is an oral small molecule inhibitor designed to treat solid tumors with specific DNA damage repair-related genomic alterations. Additionally, Repare is advancing a CCNE1-SL inhibitor program targeting tumors with CCNE1 amplification, along with a Polymerase Theta program focused on BRCA mutations and related genomic alterations. Founded in 2016, the company aims to improve cancer treatment by leveraging innovative drug discovery methods and addressing the unique vulnerabilities of tumor cells.

Dragonfly Therapeutics, Inc. is a clinical-stage biotechnology company based in Waltham, Massachusetts, focused on developing innovative therapeutics that activate immune responses against cancer. Utilizing its TriNKET platform, the company creates first-in-class drugs that target natural killer cells and other components of the innate immune system, effectively addressing immune suppressive factors within the tumor microenvironment. These novel therapies aim to enhance anti-cancer immune responses both as standalone treatments and in combination with existing cancer immunotherapies. Founded in 2015, Dragonfly Therapeutics collaborates strategically with major pharmaceutical companies, including Celgene Corporation and Merck, to advance its research and development efforts. The company's scientific founders are recognized leaders in cancer biology and immunology, driving its mission to harness the immune system's potential for breakthrough cancer treatments.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly ABI-009, aimed at treating patients with alterations in the TSC1 or TSC2 genes, where existing mTOR inhibitors have limitations in pharmacology, drug delivery, or safety. Aadi's primary focus is on providing transformational therapies for patients with ultra-rare cancers, such as perivascular epithelioid cell tumors (PEComa). Since its founding in 2011, Aadi Bioscience has aimed to address significant unmet medical needs in oncology and related therapeutic areas.

Arrakis Therapeutics, Inc. is a biopharmaceutical company focused on developing a proprietary platform for drug discovery that targets ribonucleic acid (RNA). The company aims to identify new RNA targets and create small-molecule drug candidates, primarily addressing cancer and other genetically validated diseases. Its innovative platform combines advanced RNA bioinformatics, structural tools, chemical biology, and medicinal chemistry, facilitating the development of RNA-targeted small molecules (rSMs). Additionally, Arrakis offers SHAPEware, a software tool designed to predict RNA secondary structures and potential ligand-binding sites. Founded in 2015, Arrakis Therapeutics is headquartered in Waltham, Massachusetts, and its work enables improved treatment options for various conditions, including neurological disorders and rare genetic diseases.

Delinia, Inc. is a biotechnology company based in San Francisco, California, focused on developing novel therapeutics for autoimmune and inflammatory diseases. Founded in 2014, the company’s lead program features a molecule that selectively potentiates and expands regulatory T cells (Tregs), which play a vital role in maintaining self-tolerance and immune system balance. With a team of scientific founders and experienced executives, Delinia aims to advance its therapeutics through clinical development, providing enhanced treatment options for patients suffering from autoimmune conditions. In 2017, Delinia became a subsidiary of Celgene Corporation, further strengthening its position in the biotechnology landscape.

Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative immunotherapy aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology can be applied across a wide range of clinical indications, targeting both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens for precise therapy, Anokion aims to provide effective treatment options that minimize side effects, thereby improving patient outcomes in the management of autoimmune and allergic diseases.

Acetylon Pharmaceuticals, Inc. is focused on developing small molecule drugs that target epigenetic mechanisms to improve therapeutic outcomes in cancer and other serious diseases. Established in 2008 and headquartered in Boston, Massachusetts, the company has created a proprietary platform that has led to a portfolio of optimized selective compounds for oral administration, specifically targeting Class I and Class II histone deacetylases. Among its lead drug candidates are ACY-1215 and ACY-241, which are selective HDAC6 inhibitors currently undergoing Phase 2 and Phase 1b clinical trials for the treatment of multiple myeloma. Acetylon Pharmaceuticals operates as a subsidiary of Celgene Corporation, emphasizing its commitment to addressing critical unmet medical needs through innovative epigenetic therapies.

EngMab AG is a biotechnology company based in Pfaffikon, Switzerland, founded in 2013. The company focuses on developing engineered monoclonal antibody-based therapies that enhance immune responses against tumors. EngMab's key projects include T-cell bispecific antibodies designed to address significant medical needs in hematological malignancies, as well as targeting tumor antigens present in both hematological and solid tumors. These innovative therapies aim to improve the efficacy of immune attacks on malignant cells. EngMab is funded by private Swiss investors and operates independently, although it was previously a subsidiary of Celgene Corporation.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Oncorus, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently in Phase I clinical trials aimed at treating various cancers. In addition to ONCR-177, Oncorus is advancing the ONCR-GBM program for brain cancer and exploring synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has entered a collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s immunotherapy. Founded in 2015 and headquartered in Cambridge, Massachusetts, Oncorus is committed to advancing cancer care and has pledged to support cancer research and healthcare initiatives in developing regions through corporate philanthropy.

Sapience Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of peptide-based therapeutics aimed at treating high mortality cancers. Founded in 2015 and headquartered in Harrison, New York, the company focuses on advancing innovative treatments for major unmet medical needs, particularly glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Its lead product, ST101, functions as an inhibitor of C/EBPß, a transcription factor that is often overexpressed in various cancers and plays a role in cellular differentiation, tumor survival, and proliferation. ST101 targets and reduces the expression of several genes and proteins linked to cancer cell survival and growth, inducing selective cytotoxicity across multiple tumor types, including breast cancer, melanoma, prostate cancer, GBM, lung cancer, and acute myeloid leukemia. Through its research, Sapience Therapeutics aims to translate scientific advancements into effective therapies that address oncogenic and immune dysregulation in cancer.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Agenovir Corporation is focused on the research and development of antiviral therapeutics aimed at tackling diseases linked to latent or persistent viral reservoirs. The company employs advanced nucleases, including CRISPR/Cas9 technology, to precisely target and disrupt viral DNA. Established in 2014 and headquartered in South San Francisco, California, Agenovir operates as a subsidiary of Vir Biotechnology, Inc. Its innovative approach seeks to create a new class of nuclease-based antiviral therapeutics that can effectively eliminate pathogenic viral genomes, thereby providing healthcare providers with tools to treat patients suffering from severe and persistent viral infections.

IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.

RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It focuses on discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. RAPT's proprietary discovery engine has led to the advancement of two drug candidates: FLX475, which selectively inhibits the migration of immunosuppressive regulatory T cells into tumors, and RPT193, which targets type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short time frame since the company's inception. Additionally, RAPT is exploring further therapeutic targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are currently in the discovery phase.

Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.

Aitia specializes in applying Causal AI and Digital Twins to advance drug discovery and development. The company utilizes multi-omic patient data and high-performance computing to uncover the underlying biological mechanisms of diseases, creating Digital Twins for conditions such as oncology, neurodegenerative disorders, and immunology. Their Gemini Digital Twins are actively employed to explore new therapies and expedite research and development in areas like multiple myeloma, prostate cancer, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease, with additional projects in the pipeline. Aitia collaborates with seven of the top ten pharmaceutical companies, academic research institutions, medical societies, multi-omic data firms, and patient advocacy organizations, positioning itself as a leader in the innovative intersection of technology and healthcare.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapies that leverage the biology of DNA repair for cancer treatment and synthetic lethality in autoimmune diseases. The company utilizes its expertise in DNA damage response biology to create a pipeline of small molecule therapeutics aimed at selectively targeting vulnerabilities in cancer cells and inducing their self-destruction through DNA damage overload. Cyteir's lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, which is crucial for repairing double-strand DNA breaks. The company is dedicated to addressing a variety of hematological malignancies, solid tumors, and chronic autoimmune disorders through its integrated drug development platform. Founded in 2012, Cyteir is committed to advancing next-generation therapies that can improve patient outcomes in challenging disease states.

Receptos, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, specializing in the discovery and development of therapeutics for immune disorders. The company’s lead product, ozanimod, is an oral therapy currently undergoing phase III trials for relapsing multiple sclerosis and phase II trials for ulcerative colitis and Crohn's disease. Additionally, Receptos is developing RPC4046, a monoclonal antibody in phase II trials for eosinophilic esophagitis, an allergic and immune-mediated condition. The company is also engaged in research on glucagon-like peptide-1 receptor small molecule positive allosteric modulators, which are in preclinical studies for treating Type 2 diabetes. Founded in 2008, Receptos was initially known as Receptor Pharmaceuticals, Inc. and rebranded in May 2009. As of August 2015, Receptos operates as a subsidiary of Celgene Corporation.

Lycera is a preclinical-stage biopharmaceutical company dedicated to the development of small molecule immunomodulators aimed at treating autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease. The company specializes in creating first-in-class drugs that utilize proprietary small molecules to modulate key targets involved in cellular bioenergetics and the Th17 pathway. Lycera's innovative approach seeks to provide effective oral therapies that minimize the adverse effects commonly associated with existing antiproliferative and immunosuppressive treatments. By focusing on the development of these novel agents, Lycera aims to improve patient outcomes in the management of immune disorders.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.

Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Quanticel Pharmaceuticals is a privately held drug discovery company focused on creating innovative medicines for cancer treatment. The company utilizes a proprietary platform for single-cell genomic analysis, which facilitates the identification and development of first-in-class oncology therapeutics. By concentrating on breakthrough treatments, Quanticel aims to address unmet medical needs in the fight against cancer and other life-threatening diseases.

Flexus Biosciences is a privately-held biopharmaceutical company established in 2013 and headquartered in San Carlos, California. The company specializes in the creation, development, and commercialization of innovative anti-cancer therapeutics, particularly through the application of insights in immunology. Flexus focuses on developing small-molecule cancer therapeutics that specifically target regulatory T cells. This targeted approach aims to enhance the effectiveness of cancer treatments, enabling healthcare providers to better address the complexities of cancer care.

Sequenta is a biotech company focused on developing clinical diagnostics that leverage a novel platform for assessing immune system status. Founded in 2008 by entrepreneurs with prior experience in the biotech sector, Sequenta aims to create innovative methods for measuring the immune cell receptor genes, which represent the most variable segment of the human genome. The advancements in DNA sequencing technology have enabled the company to devise unique approaches that can inform numerous clinical decisions through a single, powerful assay. By tapping into the genetic diversity of immune cell receptors, Sequenta addresses critical health conditions and disease management, positioning itself as a significant player in the field of clinical diagnostics.

VentiRx Pharmaceuticals is a clinical stage biopharmaceutical company based in Seattle, Washington, focused on developing and commercializing immunotherapies targeting Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Founded in 2006, the company’s lead investigational drug, Motolimod, works by mobilizing the patient's immune system to fight cancer through the activation of myeloid dendritic cells, monocytes, and natural killer cells. VentiRx's product pipeline includes VTX-2337, a TLR8 agonist aimed at enhancing immune responses against solid tumors and specific cancers such as ovarian and breast cancer, as well as VTX-1463, designed to address allergies. The company is also exploring TLR8 antagonists for autoimmune diseases and compounds intended as vaccine adjuvants. VentiRx Pharmaceuticals operates as a subsidiary of Celgene Corporation and has additional operations in San Diego.

Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of novel epigenetic medicines for cancer and other serious diseases. The company has developed Tazemetostat, an EZH2 inhibitor approved for the treatment of metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed follicular lymphoma and high-risk diffuse large B-cell lymphoma, as well as in patients with platinum-resistant solid tumors and castration-resistant prostate cancer. Epizyme also works on other product candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, along with inhibitors targeting PRMT5 and PRMT1 for different types of cancers. Established in 2007, Epizyme collaborates with several prominent organizations to advance its research and development efforts.

NantHealth is a healthcare company focused on transforming the delivery of care through an evidence-based platform that integrates science and technology. The company specializes in precision medicine, developing software and hardware that collect, index, analyze, and interpret molecular, financial, clinical, and operational data. This comprehensive approach aims to empower physicians, patients, payers, and researchers by providing them with crucial information to make informed decisions. NantHealth's solutions enhance diagnostics, enabling better identification and targeting of specific disease characteristics, particularly in cancer care. By promoting an integrated, genomically-informed, and personalized approach, the company seeks to advance clinical delivery and foster overall wellness in healthcare.

Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.

Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.

Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.

NantHealth is a healthcare company focused on transforming the delivery of care through an evidence-based platform that integrates science and technology. The company specializes in precision medicine, developing software and hardware that collect, index, analyze, and interpret molecular, financial, clinical, and operational data. This comprehensive approach aims to empower physicians, patients, payers, and researchers by providing them with crucial information to make informed decisions. NantHealth's solutions enhance diagnostics, enabling better identification and targeting of specific disease characteristics, particularly in cancer care. By promoting an integrated, genomically-informed, and personalized approach, the company seeks to advance clinical delivery and foster overall wellness in healthcare.

Acetylon Pharmaceuticals, Inc. is focused on developing small molecule drugs that target epigenetic mechanisms to improve therapeutic outcomes in cancer and other serious diseases. Established in 2008 and headquartered in Boston, Massachusetts, the company has created a proprietary platform that has led to a portfolio of optimized selective compounds for oral administration, specifically targeting Class I and Class II histone deacetylases. Among its lead drug candidates are ACY-1215 and ACY-241, which are selective HDAC6 inhibitors currently undergoing Phase 2 and Phase 1b clinical trials for the treatment of multiple myeloma. Acetylon Pharmaceuticals operates as a subsidiary of Celgene Corporation, emphasizing its commitment to addressing critical unmet medical needs through innovative epigenetic therapies.

Tengion is a clinical-stage biotechnology company focused on regenerative medicine, specializing in the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Tengion Neo-Bladder Augment, aimed at treating children with neurogenic bladder due to spina bifida and adults with neurogenic bladder resulting from spinal cord injury. Tengion's innovative approach seeks to eliminate the need for donor organs or anti-rejection medications by creating living cellular products that can regenerate or replace damaged tissues and organs. Additionally, the company has an investigational new drug application for its Neo-Urinary Conduit and plans to initiate a Phase 1 clinical trial for bladder cancer patients requiring bladder removal. Through its proprietary technology, Tengion aims to enhance patient outcomes by offering alternative solutions for organ and tissue repair.

Acetylon Pharmaceuticals, Inc. is focused on developing small molecule drugs that target epigenetic mechanisms to improve therapeutic outcomes in cancer and other serious diseases. Established in 2008 and headquartered in Boston, Massachusetts, the company has created a proprietary platform that has led to a portfolio of optimized selective compounds for oral administration, specifically targeting Class I and Class II histone deacetylases. Among its lead drug candidates are ACY-1215 and ACY-241, which are selective HDAC6 inhibitors currently undergoing Phase 2 and Phase 1b clinical trials for the treatment of multiple myeloma. Acetylon Pharmaceuticals operates as a subsidiary of Celgene Corporation, emphasizing its commitment to addressing critical unmet medical needs through innovative epigenetic therapies.

Avila Therapeutics is focused on designing and developing covalent drugs aimed at treating viral infections, cancers, and autoimmune diseases. One of its key products is AVL-181, a small molecule that acts as a protease inhibitor for hepatitis C virus. Founded in 2006 and based in Waltham, Massachusetts, Avila Therapeutics operates as a subsidiary of Celgene Corporation, following its acquisition in 2012. The company has also established a strategic alliance with Sanofi-Aventis to enhance its research and development efforts.

Acceleron Pharma Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics aimed at treating serious and rare diseases. Based in Cambridge, Massachusetts, the company focuses on developing novel biotherapeutics that modulate growth factors related to bone, muscle, fat, and vascular health. Its product portfolio includes luspatercept-aamt, marketed as REBLOZYL, for treating anemia in adult patients with beta-thalassemia, and candidates such as Sotatercept for pulmonary arterial hypertension. Additionally, Acceleron is advancing ACE-083, a neuromuscular treatment currently in Phase II trials for Charcot-Marie-Tooth disease. The company collaborates with partners like Celgene Corporation and Fulcrum Therapeutics to develop therapies targeting specific pathways in pulmonary diseases. Founded in 2003, Acceleron Pharma continues to focus on creating innovative treatments for conditions such as cancer-related bone loss, muscle degeneration, and metabolic disorders.

Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of medicines targeting cellular metabolism and related areas, including hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO, an oral targeted inhibitor for treating relapsed or refractory acute myeloid leukemia (AML) in adult patients, and IDHIFA, which is also aimed at AML patients with specific mutations. Agios is advancing several drug candidates through various stages of clinical trials, including TIBSOVO for frontline AML and cholangiocarcinoma, mitapivat for pyruvate kinase deficiency and thalassemia, and vorasidenib for solid tumors. The company emphasizes a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for early proof of concept and accelerated approval. Agios Pharmaceuticals was established in 2007 and has evolved from its original name, Cancer Metabolism Therapeutics, to its current identity.

Abraxis BioScience, Inc. is a biotechnology company that specializes in the discovery, development, and delivery of advanced therapeutics and core technologies aimed at treating cancer and other critical illnesses. The company is known for its flagship product, Abraxane, a nanoparticle chemotherapeutic compound utilizing proprietary tumor-targeting technology for the treatment of metastatic breast cancer. In addition to Abraxane, Abraxis BioScience's portfolio includes several clinical product candidates, such as ABI-008, a solvent-free form of docetaxel for hormone refractory prostate and metastatic breast cancer; ABI-009, an mTOR inhibitor for solid tumors; ABI-010, a polyketide inhibitor targeting heat shock protein 90; ABI-011, a thiocolchicine dimer for disrupting cancer cell processes; and Coroxane, aimed at coronary and peripheral artery restenosis. The company has established strategic partnerships with various pharmaceutical firms to enhance its research and development efforts. Founded in Los Angeles, California, Abraxis BioScience was previously known as New Abraxis, Inc. and underwent a name change in November 2007. In 2010, it was acquired by a larger pharmaceutical company.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of medicines targeting cellular metabolism and related areas, including hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO, an oral targeted inhibitor for treating relapsed or refractory acute myeloid leukemia (AML) in adult patients, and IDHIFA, which is also aimed at AML patients with specific mutations. Agios is advancing several drug candidates through various stages of clinical trials, including TIBSOVO for frontline AML and cholangiocarcinoma, mitapivat for pyruvate kinase deficiency and thalassemia, and vorasidenib for solid tumors. The company emphasizes a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for early proof of concept and accelerated approval. Agios Pharmaceuticals was established in 2007 and has evolved from its original name, Cancer Metabolism Therapeutics, to its current identity.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing cancer therapeutics, specifically targeting hematological malignancies. Owned by Celgene, the company specializes in acquiring clinical-stage oncology drug candidates and advancing them through regulatory approval and commercialization. Its primary compound, romidepsin, is a late-stage drug candidate classified as a histone deacetylase (HDAC) inhibitor. Romidepsin has demonstrated potential efficacy for various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of several classes of HDACs, thus positioning the company as a significant player in the oncology therapeutic landscape.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.

Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.

Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

Signal Pharmaceuticals is a biopharmaceutical company based in California, founded by David Anderson, Alan Lewis, Mark Carmen, and Jackie Johnson. The company specializes in the research and development of small-molecule drugs aimed at regulating the expression of genes associated with various diseases. In 2009, Signal Pharmaceuticals was acquired by Celgene, broadening its impact in the biopharmaceutical sector.